Karuna push­es back KarXT da­ta read­outs; Vir, GSK end flu col­lab­o­ra­tion; Si­lence’s $10M mile­stone pay­ment

Plus, news about Co­gent and In­di­v­ior:

Karuna de­lays some KarXT read­outs: As the drug­mak­er awaits clos­ing of its large ex­it to Bris­tol My­ers Squibb and a Sep­tem­ber FDA de­ci­sion on its schiz­o­phre­nia drug, the biotech said it has de­layed a trio of study read­outs for the can­di­date, known as KarXT. Topline da­ta from the ARISE study in schiz­o­phre­nia acute psy­chosis are now ex­pect­ed in 2025 rather than the back half of this year, and read­outs from the two ADEPT tri­als in Alzheimer’s dis­ease psy­chosis are now slat­ed for 2026 rather than 2025, William Blair an­a­lyst Myles Minter not­ed. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER